Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,007.46 -1,201.62 (-1.87%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
Eupraxia Pharmaceuticals Inc. (EPRX.TO)
| Previous close | 3.9000 |
| Open | 3.8900 |
| Bid | 3.7300 x N/A |
| Ask | 3.7500 x N/A |
| Day's range | 3.7300 - 3.8900 |
| 52-week range | 3.4400 - 9.1000 |
| Volume | |
| Avg. volume | 68,096 |
| Market cap | 132.872M |
| Beta (5Y monthly) | 1.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- CNW Group
Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024.
- PR Newswire
Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that senior management will deliver a corporate presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto.
- CNW Group
Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, announced today that trading of the Company's common shares will begin today, April 5, 2024, on the Nasdaq Capital Market ("Nasdaq"), under the ticker symbol "EPRX".
